Synvista Therapeutics Announces Initiation Of Phase 2 Study With Alagebrium For Chronic Heart Failure
Synvista Therapeutics, Inc. (AMEX: SYI) announced , dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). [click link for full article]
More: continued here
Filed under: Cardiovascular on November 18th, 2007